|
|
|
| Webinar: Scaling For Commercial Success: Accelerating Late-Stage Biologics Through Platform-Based Manufacturing | As biologics programs move toward commercialization, manufacturing strategy becomes critical. This webinar with Avid Bioservices explores how platform-based approaches can reduce risk, accelerate timelines, and improve consistency across technology transfer and scale-up. Discover practical considerations for capacity planning, supply chain readiness, and manufacturing infrastructure to help support commercial growth while maintaining quality, supply continuity, and regulatory compliance. Click here to learn more. |
|
|
|
| Reliability By Design For Single-Use Bioprocessing | White Paper | By Galen Dao, Sanisure | Success in single-use bioprocessing depends on design, supply, validation, and compliance. Learn how these factors support reliable, scalable, and resilient operations. |
|
|
| Sterile Injectable Outsourcing Trends | Article | August Bioservices | Complex sterile injectables need more than fill-finish capacity. Integrating formulation, analytics, and aseptic filling reduces risk, preserves data, and speeds commercialization. |
|
|
|
|
|
By Louis Garguilo, Chief Editor, Outsourced Pharma | The biopharmaceutical's “Valley of Death” is entered through a desert of dwindling funding. Chief Editor Louis Garguilo talks with two consultants on avoiding financial failure when outsourcing development and manufacturing. The many contributing factors for failure may have a common denominator: Project Management is an overlooked financial savior. | |
|
|
Globalization vs. Localization: Where To Outsource In A Changing World | By Jeffrey S. Buguliskis, Ph.D., Deputy Chief Editor, Outsourced Pharma | Geographical strategy for outsourcing is a pressing issue: balancing historical global supply chains with current pressures to reshore/nearshore parts of operations. In this fireside chat, editorial board members Lynn Cinelli, and Kent Pryor help us navigate the geographical pressures of modern outsourcing, the root causes of global supply chain breakdowns, the hardest assets to move across regions, and whether time-sensitive sponsors should simplify their chain or hunt for best-in-class partners globally. |
|
|
INDUSTRY INSIGHTS CONTINUED |
|
|
|
|
| Unlocking ROI And Efficiency In Drug Development | Infographic | Thermo Fisher Scientific | This analysis modeled the eNPV gains, ROI, and timeline reductions possible when CDMO functions are consolidated, finding consistent benefits across mAbs, small molecules, and development phases. |
|
|
| Platform Strategy For Improving Efficacy In Bispecific Antibodies | Article | By Wooseok Yang, Ph.D., and Kihong Kim, Samsung Biologics | Novel bispecific antibody engineering overcomes assembly and manufacturability challenges, enabling scalable production while preserving therapeutic function, stability, purity, and product quality. |
|
|
| A New Approach To Regulatory Compliance In Korea | Article | Curia | Navigating Asian pharma markets requires alignment with local regulations. Standardized documentation, facility registrations, and strong quality systems support compliance and reliable supply. |
|
|
| Vial Fogging: Practical Considerations For Vial Selection | White Paper | By Gregory Sacha, Ph.D; and Kevin Bond, Ph.D., Simtra BioPharma Solutions | Vial fogging is a common phenomenon observed in lyophilized biologic drug products. Assimilate the critical factors contributing to vial fogging and inform vial selection decisions. |
|
|
|
|
|
|
|
|
|
|
|
|
OUTSOURCED PHARMA CAPABILITIES UPDATE |
|
|
|
CDMOs in biologics, cell and gene, and small molecule share their capabilities and available capabilities. See for yourself why this virtual event has become a wildly popular resource to identify options for your development and manufacturing needs. |
|
|
| Connect With Outsourced Pharma: |
|
|
|
